President Abraham Morgentaler, MD welcomes you to the Androgen Society 2nd Annual Meeting.
TABLE OF CONTENTS

Androgen Society

2nd Annual Meeting
March 21 – 22, 2019
Hilton New Orleans Riverside
New Orleans, Louisiana

Welcome Message .............................................................................................................2
2018 - 2019 Board of Directors ..........................................................................................2
CME Information.................................................................................................................3
Faculty Disclosure Report ..................................................................................................4
Scientific Program ...............................................................................................................8
Speaker Biographies ..........................................................................................................12
Industry Satellite Symposium Event .................................................................................17
Industry Support ...............................................................................................................18
Exhibit Hall Floor Plan ......................................................................................................20

GENERAL MEETING INFORMATION

Registration/Information Desk Hours
Location: The District Foyer
Thursday, March 21, 2019  6:30 a.m. – 5:30 p.m.
Friday, March 22, 2019  6:30 a.m. – 6:15 p.m.

Exhibit Hall Hours
Location Jefferson Ballroom
Thursday, March 21, 2019  7:00 a.m. – 6:30 p.m.
Friday, March 22, 2019  10:00 a.m. – 4:00 p.m.

Welcome Reception
Location: Jefferson Ballroom
Thursday, March 21, 2019  5:30 p.m. – 6:30 p.m.
Dear Colleagues and Friends,

On behalf of the Board of the Androgen Society, it is my distinct honor to welcome you to the 2nd Annual Meeting of the Androgen Society, to be held March 21 – 22, 2019 at the Hilton New Orleans Riverside in New Orleans, Louisiana, USA. The Androgen Society was created to provide the first professional meeting entirely dedicated to testosterone deficiency and its treatment, and our first meeting in February 2018 in Lisbon, Portugal was a truly historic event. Leaning on that initial success, we have expanded our program this year to two full days, added an abstract session, and initiated award sessions for excellence in the field. Our goal is to provide the premier educational experience in the field of testosterone deficiency.

Highlights of this year’s meeting include a Guidelines Showdown between the Endocrine Society, the American Urological Association, and the European Association of Urology. There will be an extended session on the use of testosterone in women. Other key topics to be covered include testosterone and the brain, testosterone and cardiovascular effects, the current status of testosterone in men with prostate cancer, and the exciting area of testosterone and metabolic disease, particularly obesity and diabetes. We are especially excited to have Dr. Tamara Wexler from NYU Langone Medical Center deliver our keynote address on the fascinating and socially relevant topic of elevated endogenous testosterone in elite female athletes and newly instituted regulations. The title of her lecture is Hyperandrogenism and Leveling the Playing Field in the Elite Female Athlete.

All of us in research and clinical medicine stand on the shoulders of the men and women who helped show us the way forward. The Androgen Society this year will honor Ronald Swerdloff with the Lifetime Achievement Award, and Bruno Lunenfeld with the Dedication to Education Award.

A key feature for any meeting is the opportunity to interact with colleagues, new and old, to foster relationships and research. The relatively small scale of this meeting is designed to foster these important interactions.

We look forward to seeing you at the 2nd Annual Meeting of the Androgen Society in New Orleans!

Sincerely,
Abraham Morgentaler, MD
President

ANDRO BOARD OF DIRECTORS 2018 - 2019

OFFICERS

President
Abraham Morgentaler, MD

Officers
Abdul Traish, MBA, PhD
Hugh Jones, MD
Martin Miner, MD
Peter Lim, MD

Program Planning Committee
Abraham Morgentaler, MD, Program Chair
Hugh Jones, MD
Peter Lim, MD
Martin Miner, MD
Abdul Traish, MBA, PhD

EXECUTIVE OFFICE

Executive Director
Heather Swanson

Associate Director
Thomas Heidrich

ANDRO Executive Office
1100 E. Woodfield Road, Suite 350
Schaumburg, IL 60173
Phone: (847) 517-7225
Fax: (847) 517-7229
androgensociety@wjweiser.com
Educational Needs

Testosterone (T) deficiency, also known as hypogonadism, has a wide variety of effects in men and women. Although T therapy has been available since the 1930s, it is only within the last 15-20 years that treatment has become relatively common, leaving many key clinical questions unanswered or in evolution. Clinical research to guide evidence-based practice continues to provide new information of considerable importance to patients, physicians, and researchers. However, there is limited opportunity for physicians to familiarize themselves with these evolving diagnostic and therapeutic approaches outside of CME events.

The goal of the annual meeting of the Androgen Society is to promote excellence in research, education, and clinical practice with regards to T deficiency and its treatment. Formats for educational sessions will include lectures, reviews of large randomized and observational studies, debates, and panel discussions. Many controversial issues will be addressed, including the use of testosterone in men with prostate cancer, the postulated cardiovascular risks and benefits of T therapy, the use of T therapy in women, and the growing field of research showing important effects of T therapy on metabolic conditions, especially diabetes. Practitioners will gain enormously from attending this meeting, with benefits ranging from practical tips on patient management to an understanding of molecular pathways by which testosterone influences endothelial and pancreatic beta cell function.

Educational Objectives

At the conclusion of the Meeting, attendees will be able to:
1. Employ an evidence-based algorithm for approaching the diagnostic and therapeutic management of men with testosterone deficiency.
2. Identify novel management options for T deficiency.
3. Identify the role of regenerative medicine in the management of T deficiency.
4. Identify controversies in testosterone therapy including cardiovascular risk and use in prostate cancer patients.
5. Describe the origin of the concern that testosterone is risky for men with prostate cancer.
6. Identify which patient is a candidate for treatment based on various published guidelines.
7. Discuss how to approach testosterone deficiency in women.
8. Explain the effects of testosterone deficiency and treatment on fat cells, muscle cells, and obesity.
9. Discuss the basis for the controversy regarding cardiovascular risk with testosterone therapy.
10. Identify which patients with prostate cancer may be considered reasonable candidates for T therapy.

Accreditation Statement

SAPS CME ACCREDITATION STATEMENT:
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Medical Association of Georgia through the joint providership of the Southern Alliance for Physician Specialties CME and the Androgen Society. The Southern Alliance for Physician Specialties CME is accredited by the Medical Association of Georgia to provide continuing medical education for physicians.

The Southern Alliance for Physician Specialties CME designates this live activity for a maximum of 14.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Non-physician healthcare professionals will receive a Certificate of Completion. For information on the applicability and acceptance of Certificates of Completion for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME, please consult your professional licensing board.

General Disclaimer

The statements and opinions contained in this program are solely those of the individual authors and contributors and not of the Androgen Society. The appearance of the advertisements is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality, or safety. The content of this publication may contain discussion of off-label uses of some of the agents mentioned. Please consult the prescribing information for full disclosure of approved uses. The Androgen Society disclaims responsibility for any injury to persons or property resulting from any ideas or products referred to in the abstracts or advertisements.

Special Assistance

We encourage participation by all individuals. If you have a disability, advance notification of any special needs will help us better serve you. Call (847) 517–7225 if you require special assistance to fully participate in the meeting.
In accordance with the ACCME Accreditation Criteria, the Southern Alliance for Physician Specialties (SAPS), as the accredited provider of this activity, must ensure that anyone in a position to control the content of the educational activity has disclosed all relevant financial relationships with any commercial interest. Therefore, it is mandatory that both the program planning committee and speakers complete disclosure forms. Members of the program committee were required to disclose all financial relationships and speakers were required to disclose any financial relationship as it pertains to the content of the presentations. The ACCME defines a ‘commercial interest’ as “any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients”. It does not consider providers of clinical service directly to patients to be commercial interests. The ACCME considers “relevant” financial relationships as financial transactions (in any amount) that may create a conflict of interest and occur within the 12 months preceding the time that the individual is being asked to assume a role controlling content of the educational activity.

The requirement for disclosure is not intended to imply any impropriety of such relationships, but simply to identify such relationships through full disclosure and to allow the audience to form its own judgments regarding the presentation.

<table>
<thead>
<tr>
<th>PLANNING COMMITTEE / CME ORGANIZERS</th>
<th>DISCLOSURE</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Company</td>
</tr>
<tr>
<td>JONES, MD, Thomas</td>
<td>Ferring UK, Mereo Biopharma UK</td>
</tr>
<tr>
<td>CME Organizer, Speaker, Moderator</td>
<td></td>
</tr>
<tr>
<td>LIM, MD, Peter</td>
<td>Basin, Bayer</td>
</tr>
<tr>
<td>CME Organizer, Moderator</td>
<td></td>
</tr>
<tr>
<td>MINER, MD, Martin</td>
<td>Antares Pharm</td>
</tr>
<tr>
<td>CME Organizer, Speaker, Moderator</td>
<td></td>
</tr>
<tr>
<td>MORGENTALER, MD, Abraham</td>
<td>Aytu, Acerus</td>
</tr>
<tr>
<td>CME Organizer, Speaker, Moderator</td>
<td></td>
</tr>
<tr>
<td>MHB Labs</td>
<td>Endo</td>
</tr>
<tr>
<td></td>
<td>Stock Shareholder (Directly Purchased)</td>
</tr>
<tr>
<td>TRAISH, MBA, PhD, Abdulmaged</td>
<td>Nothing to disclose</td>
</tr>
<tr>
<td>CME Organizer, Speaker, Moderator</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>SPEAKERS / MODERATORS / PANELISTS / DISCUSSANTS / CO-AUTHORS</th>
<th>DISCLOSURE</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Company</td>
</tr>
<tr>
<td>ANAWALT, MD, Bradley</td>
<td>Nothing to disclose</td>
</tr>
<tr>
<td>Speaker</td>
<td></td>
</tr>
<tr>
<td>CUNNINGHAM, MD, Glenn</td>
<td>AbbVie, Aytu Bioscience, Clarus, Merck, Transition Therapeutics</td>
</tr>
<tr>
<td>Speaker, Moderator</td>
<td></td>
</tr>
<tr>
<td>DANDONA, MD, Paresh</td>
<td>AbbVie, Astra Zeneca, Novo Nordisk</td>
</tr>
<tr>
<td>Speaker</td>
<td></td>
</tr>
<tr>
<td></td>
<td>AbbVie, Astra Zeneca, Novo Nordisk</td>
</tr>
<tr>
<td>SPEAKERS / MODERATORS / PANELISTS / DISCUSSANTS / CO-AUTHORS</td>
<td>DISCLOSURE</td>
</tr>
<tr>
<td>-------------------------------------------------------------</td>
<td>------------</td>
</tr>
<tr>
<td></td>
<td>Company</td>
</tr>
<tr>
<td>DAVID, MRCGP, FECSM, Janine Panelist</td>
<td>Besins Healthcare (UK) Ltd, Bayer Healthcare, Ferring Pharmaceuticals</td>
</tr>
<tr>
<td></td>
<td>Besins Healthcare (UK) Ltd, Bayer Healthcare</td>
</tr>
<tr>
<td>DESILVA, MD, Derrick Speaker, Panelist</td>
<td>Nothing to disclose</td>
</tr>
<tr>
<td>DESLYPERE, MD, PhD, Jean Paul Speaker, Moderator</td>
<td>Nothing to disclose</td>
</tr>
<tr>
<td>DHINDSA, MD, FACE, Sandeep Speaker</td>
<td>Nothing to disclose</td>
</tr>
<tr>
<td>DOBS, MD, MHS, Adrian Speaker, Moderator, Panelist</td>
<td>Nothing to disclose</td>
</tr>
<tr>
<td>ELLIOTT, MD, Stacy Moderator</td>
<td>Acerus Pharmaceuticals</td>
</tr>
<tr>
<td>GRAZIOTTIN, MD, Alessandra Panelist</td>
<td>Angelini, Bayer, Berlin-Chemie, Biofemme, Italfarmaco, Gedeon-Richter, Lo.Li.Pharma, Recordati, Shionogi, Zambon, Teva</td>
</tr>
<tr>
<td></td>
<td>Alfa Wassermann, Angelini, Mylan, Shionogi</td>
</tr>
<tr>
<td></td>
<td>Angelini, Alfa Wassermann, Bayer, Italfarmaco, Gedeon-Richter, Lo.Li. Pharma, Recordati, Shionogi, Zambon</td>
</tr>
<tr>
<td>GREENBERG, MD, David Moderator</td>
<td>Acerus Pharmaceuticals</td>
</tr>
<tr>
<td>HACKETT, MD, Geoffrey Speaker, Moderator</td>
<td>Besins Healthcare</td>
</tr>
<tr>
<td>HEIDELBAUGH, Joel Speaker</td>
<td>Nothing to disclose</td>
</tr>
<tr>
<td>HELLOSTROM, MD, FACS, Wayne J. Speaker</td>
<td>NIH, Theralogix</td>
</tr>
<tr>
<td></td>
<td>Abbvie, Allergan, Boston Scientific, Coloplast, Futura, Pfizer, Virility</td>
</tr>
<tr>
<td></td>
<td>Endo</td>
</tr>
<tr>
<td></td>
<td>New England Research Institute</td>
</tr>
<tr>
<td>HSIEH, MD, Tung-Chin Speaker</td>
<td>Endo Pharmaceutical</td>
</tr>
<tr>
<td>JONES, MD, Thomas Speaker, Moderator</td>
<td>Ferring UK, Mereo Biopharma UK</td>
</tr>
<tr>
<td>KELLY, Daniel Speaker</td>
<td>Bayer</td>
</tr>
<tr>
<td>KHERA, MD, MBA, MPH, Mohit Speaker, Moderator</td>
<td>AbbVie, Endo, Boston Scientific, Coloplast</td>
</tr>
</tbody>
</table>
## FACULTY DISCLOSURE REPORT

### Table of Contents
- The Androgen Society 2nd Annual Meeting

### SPEAKERS / MODERATORS / PANELISTS / DISCUSSIONANTS / CO-AUTHORS

<table>
<thead>
<tr>
<th>Name</th>
<th>Role</th>
<th>Company</th>
<th>Role with Commercial Interest</th>
<th>Nature of Relationship</th>
</tr>
</thead>
<tbody>
<tr>
<td>KIM, PhD, Noel</td>
<td>Speaker</td>
<td>Valeant Pharmaceuticals</td>
<td>Grants/Research Support</td>
<td>Principal Investigator</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Sprout Pharmaceuticals</td>
<td>Grants/Research Support</td>
<td>Principal Investigator</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Sprout Pharmaceuticals</td>
<td>Consultant</td>
<td>Consulting</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Strategic Science and Technologies</td>
<td>Consultant</td>
<td>Consulting</td>
</tr>
<tr>
<td>LEVI, Daniel</td>
<td>Speaker</td>
<td></td>
<td></td>
<td>Nothing to disclose</td>
</tr>
<tr>
<td>LIM, MD, Peter</td>
<td>Moderator</td>
<td>Basin, Bayer</td>
<td>Consultant</td>
<td>Lecturer for their CME Talks for Doctors</td>
</tr>
<tr>
<td></td>
<td></td>
<td>American Medical Systems</td>
<td>Other Financial or Material Support</td>
<td>Speaker</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Endo Pharmaceuticals</td>
<td>Consultant</td>
<td>Speaker/Consultant</td>
</tr>
<tr>
<td></td>
<td></td>
<td>AbbVie, Lipocine, Aytu Bioscience</td>
<td>Consultant</td>
<td></td>
</tr>
<tr>
<td>LIPSHULTZ, MD, Larry</td>
<td>Speaker, Moderator</td>
<td>Pfizer</td>
<td>Honorarium</td>
<td>Member of Data Safety Monitoring Board</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Pfizer, Repros</td>
<td>Stock Shareholder (Directly Purchased)</td>
<td>Stock Purchase</td>
</tr>
<tr>
<td>MCCULLOUGH, MD, Andrew</td>
<td>Panelist</td>
<td>Antares Pharm</td>
<td>Consultant</td>
<td>Consulting</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Aytu, Acerus</td>
<td>Consultant</td>
<td>Consulting Fees</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Endo</td>
<td>Grants/Research Support</td>
<td>Research</td>
</tr>
<tr>
<td></td>
<td></td>
<td>MHB Labs</td>
<td>Stock Shareholder (Directly Purchased)</td>
<td>Stock Ownership</td>
</tr>
<tr>
<td>MINER, MD, Martin</td>
<td>CME Organizer, Speaker, Moderator</td>
<td></td>
<td></td>
<td>Nothing to disclose</td>
</tr>
<tr>
<td>MORGENTALER, MD, Abraham</td>
<td>CME Organizer, Speaker, Moderator</td>
<td>AMAG Pharmaceuticals</td>
<td>Consultant</td>
<td>Advisory Board, Consultant on research</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Sprout Pharmaceuticals</td>
<td>Consultant</td>
<td>Scientific Advisor</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Dare Bioscience, Strategic Science Technologies, Therapeutics MD</td>
<td>Consultant</td>
<td>Consultant on Drug Development Research</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JDS Therapeutics, Proctor and Gamble</td>
<td>Consultant</td>
<td></td>
</tr>
<tr>
<td>RAHEEM, MD, Omer</td>
<td>Moderator</td>
<td></td>
<td></td>
<td>Nothing to disclose</td>
</tr>
<tr>
<td>SPEAKERS / MODERATORS / PANELISTS / DISCUSSANTS / CO-AUTHORS</td>
<td>DISCLOSURE</td>
<td>Company</td>
<td>Role with Commercial Interest</td>
<td>Nature of Relationship</td>
</tr>
<tr>
<td>---------------------------------------------------------------</td>
<td>------------</td>
<td>---------</td>
<td>-------------------------------</td>
<td>------------------------</td>
</tr>
<tr>
<td>RAMACHANDRAN, PhD, Sudarshan Moderator</td>
<td></td>
<td>BESINS HEALTHCARE</td>
<td>Grants/Research Support</td>
<td>Grant to attend meeting</td>
</tr>
<tr>
<td>RAMASAMY, MD, Ranjith Speaker</td>
<td></td>
<td>Direx Systems</td>
<td>Grants/Research Support</td>
<td>Investigator</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Coloplast</td>
<td>Consultant</td>
<td>Consultant</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Endo Pharmaceuticals</td>
<td>Consultant</td>
<td>Advisory Board</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Aytu BioScience, Boston Scientific</td>
<td>Grants/Research Support</td>
<td>Investigator</td>
</tr>
<tr>
<td>RHODEN, PhD, Ernani Luis Moderator</td>
<td></td>
<td>Nothing to disclose</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Sermonix Pharmaceuticals</td>
<td>Stock Shareholder (Directly Purchased)</td>
<td>Stock Shareholder</td>
<td></td>
</tr>
<tr>
<td></td>
<td>AbbVie, Inc., AMAG Pharmaceuticals, Inc., Duchesnay USA, Novo Nordisk, Shionogi Inc., TherapeuticsMD</td>
<td>Other Financial or Material Support</td>
<td>Speaker's Bureau</td>
<td></td>
</tr>
<tr>
<td>TRAISH, MBA, PhD, Abdulmaged CME Organizer, Speaker, Moderator</td>
<td>Nothing to disclose</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>URBAN, MD, Randall Speaker</td>
<td>Nothing to disclose</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>WEXLER, Tamara Speaker</td>
<td>Strongbridge Biopharma</td>
<td>Consultant</td>
<td>Scientific Advisory Board</td>
<td></td>
</tr>
<tr>
<td>ZITZMANN, MD, PhD, Michael Speaker, Moderator</td>
<td>Nothing to disclose</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
THURSDAY, MARCH 21, 2019

OVERVIEW

6:30 a.m. - 5:30 p.m. Registration/Information Desk Hours
   Location: The District Foyer

7:00 a.m. - 6:30 p.m. Exhibit Hall Hours
   Location: Jefferson Ballroom

7:00 a.m. - 8:00 a.m. Breakfast
   Location: Jefferson Ballroom

12:00 p.m. - 1:00 p.m. Industry Satellite Symposia Lunch
   Location: Fulton

5:30 p.m. - 6:30 p.m. Welcome Reception
   Location: Jefferson Ballroom

GENERAL SESSION

8:00 a.m. - 8:15 a.m. Welcome and Presidential Address
   Speaker: Abraham Morgentaler, MD

8:15 a.m. - 9:30 a.m. Science and the Status of Testosterone in 2019
   Moderators: T. Hugh Jones, MD
               Martin Miner, MD
   Speaker: Mohit Khera, MD, MBA, MPH

8:15 a.m. - 8:30 a.m. The Status of Testosterone in 2019
   Speaker: Mohit Khera, MD, MBA, MPH

8:30 a.m. - 8:55 a.m. The Science of Testosterone in Cardiometabolic Disease
   Speaker: Daniel Kelly, PhD

8:55 a.m. - 9:30 a.m. What have We Learned from the Testosterone Trials?
   Speakers: Adrian S. Dobs, MD, MHS
            Abdul Traish, MBA, PhD

9:30 a.m. - 10:30 a.m. Guidelines
   Moderator: Mohit Khera, MD, MBA, MPH

9:30 a.m. - 10:15 a.m. Guidelines Showdown: American Urological Association (AUA), Endocrine Society, and the European Association of Urology (EAU)
   Speakers: Martin Miner, MD
            Glenn R. Cunningham, MD
            Michael Zitzmann, MD, PhD

10:15 a.m. - 10:30 a.m. Guidelines: Help or Hindrance for the Clinician?
   Speaker: Geoffrey Hackett, MD

10:30 a.m. - 11:00 a.m. Break/ Networking in the Exhibit Hall
   Location: Jefferson Ballroom

11:00 a.m. - 12:00 p.m. Abstracts
   Moderators: Adrian S. Dobs, MD, MHS
              T. Hugh Jones, MD

12:00 p.m. - 1:00 p.m. Industry Satellite Symposia Lunch
   Location: Fulton

1:00 p.m. - 1:45 p.m. New Concepts and Challenges in the Field of Testosterone
   Moderators: Peter H. Lim, MD
              Geoffrey Hackett, MD

1:00 p.m. - 2:00 p.m. Testosterone Therapy for Reduced Bone Mass
   Speaker: Joel Heidelbaugh, MD, FAAAAFP, FAGC

1:45 p.m. - 2:15 p.m. Erythrocytosis
   Moderators: Jean Paul Deslypere, MD, PhD
             David Greenberg, MD

1:45 p.m. - 2:00 p.m. Testosterone and Erythrocytosis
   Speaker: Wayne J. G. Hellstrom, MD, FACS

2:00 p.m. - 2:15 p.m. How the Endocrine Society Established its Upper Limit of Acceptable Erythrocytosis
   Speaker: Glenn R. Cunningham, MD

2:15 p.m. - 2:30 p.m. Lifetime Achievement Award Presentation*
   Recipient: Ronald Swerdloff, MD
*Not CME Accredited

2:30 p.m. - 3:00 p.m. Break/ Networking in the Exhibit Hall
   Location: Jefferson Ballroom

3:00 p.m. - 3:10 p.m. Oral Testosterone Undecanoate*
   Speaker: Ronald Swerdloff, MD
*Not CME Accredited

3:10 p.m. - 3:20 p.m. Xyosted*
   Speaker: Jed Kaminetsky, MD
*Not CME Accredited

3:20 p.m. - 3:30 p.m. Natesto*
   Speaker: Gerwin Westfield, PhD
*Not CME Accredited

3:30 p.m. - 3:45 p.m. Panel Discussion/Q&A*
*Not CME Accredited

All sessions will be located in St. James Room unless otherwise noted.
Speakers and times are subject to change.
3:45 p.m. - 4:15 p.m.  Clinical Controversies
Moderators: Martin Miner, MD
              Michael Zitzmann, MD, PhD

3:45 p.m. - 4:00 p.m.  Is it Necessary to Fast for T Testing?
Speaker: Sandeep Dhindsa, MD, FACE

4:00 p.m. - 4:15 p.m.  Does Diurnal Variation Require Early Morning Testing?
Speaker: Abraham Morgentaler, MD

4:15 p.m. - 5:30 p.m.  Testosterone and Cardiovascular Disease
Moderators: Sudarshan Ramachandran, FRCPath, PhD
              Abdul Traish, MBA, PhD

4:15 p.m. - 4:30 p.m.  CV Trial Results Since the FDA Warning 2015
Speaker: Martin Miner, MD

4:30 p.m. - 4:55 p.m.  Might T Therapy offer CV Benefits Rather than Risks?
Speaker: T. Hugh Jones, MD

4:55 p.m. - 5:30 p.m.  Testosterone Litigation Update
Speakers: Daniel Levi
          Amy Nemetz

5:30 p.m. - 6:30 p.m.  Welcome Reception
Location: Jefferson Ballroom

FRIDAY, MARCH 22, 2019

OVERVIEW

6:30 a.m. - 6:15 p.m. Registration/Information Desk Hours
Location: The District Foyer

7:00 a.m. - 8:00 a.m.  Industry Satellite Symposia Breakfast
Location: Fulton

10:00 a.m. - 4:00 p.m.  Exhibit Hall Hours
Location: Jefferson Ballroom

GENERAL SESSION

7:00 a.m. - 8:00 a.m.  Industry Satellite Symposia Breakfast
Location: Fulton

8:00 a.m. - 9:20 a.m.  Testosterone Therapy in Women
Moderators: Stacy L. Elliott, MD
            Abdul Traish, MBA, PhD

8:00 a.m. - 8:20 a.m.  ISSWSH White Paper: Women and T Therapy
Speaker: James A. Simon, MD
         CCD, NCMP, IF

8:20 a.m. - 8:45 a.m.  Androgens and the Female Genitalia
Speaker: Noel N. Kim, PhD

8:45 a.m. - 9:20 a.m.  How I Treat Women with Testosterone Deficiency
Panelists: Alessandra Graziotin, MD
          Sharon Parish, MD, IF

9:20 a.m. - 10:35 a.m.  Clinical Practice
Moderators: Abraham Morgentaler, MD
              Omer Rafeem, MD

9:20 a.m. - 9:30 a.m.  Strategies for Fertility Preservation in Men on Testosterone Therapy
Speaker: Larry I. Lipshultz, MD

9:30 a.m. - 9:45 a.m.  Effects of Nasal Testosterone Gel on Semen Parameters and Hormones
Speaker: Ranjith Ramasamy, MD

9:45 a.m. - 10:20 a.m.  Debate: Total Testosterone is the Best Test for Diagnosing T Deficiency
Speakers: Jean Paul Deslypere, MD, PhD
          Abraham Morgentaler, MD

10:20 a.m. - 10:35 a.m.  The Age Management Medicine Approach to Testosterone
Speaker: Derrick DeSilva Jr., MD

10:35 a.m. - 11:05 a.m. Break/Networking in the Exhibit Hall
Location: Jefferson Ballroom

11:05 a.m. - 12:00 p.m.  Clinical Case Discussion
Moderator: Larry I. Lipshultz, MD
Panelists: Janine David, MRCGP, FECSM
          Derrick DeSilva Jr., MD
          Adrian S. Dobs, MD, MHS
          Andrew R. McCullough, MD
          Peter Lim, MD

12:00 p.m. - 1:00 p.m.  Industry Satellite Symposia Lunch
Location: Fulton

1:00 p.m. - 1:35 p.m.  Keynote: Hyperandrogenism and Leveling the Playing Field in the Elite Female Athlete
Speaker: Tamara L. Wexler, MD, PhD

1:35 p.m. - 1:50 p.m.  Dedication to Education Award Presentation*
Recipient: Bruno Lunenfeld, MD, FRCPG, FACOG
*Not CME Accredited

1:50 p.m. - 3:10 p.m.  Brain and Etiology
Moderator: Daniel Kelly, PhD

2:25 p.m. - 2:50 p.m.  Testosterone and Opioids
Speaker: T. Mike Hsieh, MD
2:50 p.m. - 3:10 p.m.  Classical versus Functional T Deficiency - Is there a Meaningful Difference?  
Speaker: Michael Zitzmann, MD, PhD

3:10 p.m. - 3:40 p.m.  Break/ Networking in the Exhibit Hall  
Location: Jefferson Ballroom

3:40 p.m. - 5:05 p.m.  Testosterone and Diabetes  
Moderators: Glenn R. Cunningham, MD  
Geoffrey Hackett, MD

3:40 p.m. - 3:55 p.m.  The Size of the Problem - Prevalence of Testosterone Deficiency in Men with Pre-Diabetes and Type 2 Diabetes  
Speaker: Paresh Dandona, MD

3:55 p.m. - 4:10 p.m.  Who Should Receive Testosterone Replacement and Should there be a Screening Program in Men with Type 2 Diabetes?  
Speaker: Sandeep Dhindsa, MD, FACE

4:10 p.m. - 4:25 p.m.  Does Testosterone Influence Beta Cell Function*  
Speaker: Franck Mauvais-Jarvis, MD  
*Not CME Accredited

4:25 p.m. - 4:40 p.m.  How Long should Testosterone Deficient Men with Type 2 Diabetes be treated with Testosterone Replacement?*  
Speaker: Farid Saad, DVM, PhD  
*Not CME Accredited

4:40 p.m. - 5:05 p.m.  What Does the Future Hold for Testosterone Deficiency in Men with Type 2 Diabetes?  
Speaker: T. Hugh Jones, MD

5:05 p.m. - 6:15 p.m.  The Future of Testosterone Therapy  
Moderators: Emanei Luis Rhoden, MD  
Michael Zitzmann, MD, PhD

5:05 p.m. - 5:25 p.m.  Should Testosterone Therapy be Offered to treat Obesity  
Speaker: Abdul Traish, MBA, PhD

5:25 p.m. - 5:40 p.m.  Leydig Stem Cell Therapy for Increasing Testosterone: From Bench to Bedside  
Speaker: Ranjith Ramasamy, MD

5:40 p.m. - 6:15 p.m.  Can We Now Offer T Therapy to Men with Prostate Cancer?  
Speaker: Abraham Morgentaler, MD

6:15 p.m. - 6:20 p.m.  Closing Remarks & Adjournment  
Speaker: Abraham Morgentaler, MD
Bradley D. Anawalt, MD, FACP
Dr. Anawalt is the Chief of Medicine at the University of Washington Medical Center and Professor and Vice Chair of the Department of Medicine at the University of Washington. He earned his bachelor’s degree in anthropology at the University of Santa Clara and his medical degree at the University of California at Davis. Dr. Anawalt completed his internal medicine residency at the University of Washington in 1992 and served as chief resident at the Seattle VA Medical Center 1992-1993. He completed a fellowship in endocrinology at the University of Washington and joined the faculty in 1995.

Dr. Anawalt's teaching has been recognized with the Paul Beeson teaching award and the endocrine-fellowship teaching award at the University of Washington. In addition to serving as the North American Editor for Clinical Endocrinology, he serves as a consultant to the United States Anti-Doping Agency, is on the editorial board of the Journal of Clinical Endocrinology and Metabolism and served as an Associate Editor of Endocrine Reviews. He also writes questions for the American Board of Internal Medicine self-evaluation program (for board re-certification). He has done research in male infertility, male hormonal contraception and the male reproductive physiology. He lives in Seattle with his wife and three daughters.

Janine David MD FECSM
Dr. David is a GP who specializes in Men’s Health. She has been a GP partner & trainer in Portway Surgery, Porthcawl, UK since 2005 and also works as an Associate Specialist in Urology at the Princess of Wales Hospital in Wales. She has passed the Multidisciplinary Joint Committee of Sexual Medicine (MJCM) exam making her a Fellow of the European Committee of Sexual Medicine (FECSM). Dr. David has a particular interest in testosterone deficiency and has run clinical audits throughout the UK to identify ways to improve the health of patients in this often overlooked area. She is the founding member of the Primary Care Testosterone Advisory Group (www.PCTAG.uk) and she is a regular speaker both on the national (UK) and international stage.

Dr. David is also actively involved in clinical research.

Jean-Paul Deslypere, MD, PhD
Dr. Deslypere is currently the CEO of Aesculape CRO. Aesculape CRO Pte Ltd and Aesculape CRO BVBA are full service healthcare and clinical research companies with offices in Belgium, Italy, Poland, Philippines, Singapore and Malaysia. Dr. Deslypere received his medical degree summa cum laude from the University of Gent in Belgium in 1977. After graduation he obtained his PhD (Geaggregeerde van het Hoger Onderwijs) in Endocrinology and Metabolic Diseases in 1984 and his Board Certification in Internal Medicine/Endocrinology in 1987. He worked from 1977 until 1996 at the NFWO (from Aspirant till Onderzoeksleider). In 1997 he started working for the clinical trial industry, as Director International Operations of a central lab (BARC Central Lab Zwijnaarde), based in Singapore, Jakarta, Sydney, Johannesburg and New York, setting up BARC affiliates around the world. In 2000 he became Regional Director/Vice President Asia Pacific for ICON Clinical Research, based in Singapore. In 2002 he joined the Singapore Public sector (MOH) and in February 2006 Dr. Deslypere joined SGS Life Sciences as Vice President Asia Pacific Clinical Research (Singapore).

Adrian S. Dobs, MD, MHS
Dr. Dobs is presently an active investigator in the field of male gonadal function. She is particularly interested in new forms of male hormone replacement therapy and has published extensively in the area of hormonal changes with aging. Her clinical practice focused on sex hormone disorders in both men and women. As Director of the Clinical Trials Unit, she oversees a team of individuals dedicated to facilitating clinical research within an academic medical center environment. Her other administrative roles include Director of the Johns Hopkins SYSU (China) Collaboration in Clinical Research and Director of the NCI-funded Center to Reduce Cancer Disparities.

Glenn R. Cunningham, MD
Dr. Cunningham is currently the Distinguished Professor Emeritus of Medicine-Endocrinology at Baylor College of Medicine in Houston, Texas. Dr. Cunningham’s professional interests include diabetes, endocrinology, thyroid disease, osteoporosis, male hypogonadism, erectile dysfunction and Cushing’s syndrome. He received his MD from University of Oklahoma Medical School.

Dr. Cunningham completed his Residency and Fellowship at Duke University Medical Center in Durham, North Carolina. He also holds certifications in Endocrinology, Diabetes and Metabolism with the American Board of Internal Medicine.

Sandeep Dhindsa, MDFACE
Dr. Dhindsa completed his medical schooling from All India Institute of Medical Sciences in New Delhi, India. He did a residency in Internal medicine from State University of New York at Brooklyn and fellowship in Endocrinology from State University of New York at Buffalo in 2002. He is Professor of Medicine and Chief of the Division of Endocrinology and Metabolism at Saint Louis University.

His primary area of research is hypogonadism in obesity and type 2 diabetes. Dr. Dhindsa has over 70 publications in peer-review journals. He is a member of Scientific Reproductive Committee of the American Association of Clinical Endocrinologists.

Alessandra Graziottin, MD
Dr. Graziottin specialized in Obstetrics and Gynaecology, and Oncology, and is a certified Psychotherapist in Sexual Medicine.

She is the Director of the Centre of Gynaecology and Medical Sexology at the H. San Raffaele Resinati in Milano. She is the Founder and Chairman of the Alessandra Graziottin Foundation for the cure and care of pain in women NPO. She is the Consultant Professor at the Advanced Master in Andrology and Sexual Medicine of the University of Firenze and is a member of the Scientific Board for the “Comorbidity and Psychopathology” Area of the Gruppo Italiano per lo Studio della Motilità dell’Apparato Digerente (GISMAD).

Dr. Graziottin is also a member of the Core Faculty of the European School of Oncology (ESO) and a member of the permanent International Organizing Committee (IOC) of Controversies in Obstetrics, Gynecology & Infertility (COGI).

Dr. Graziottin has published 22 scientific books (as author, co-author or editor); more than 90 chapters of scientific books, 116 refereed papers and more than 300 proceeding contributions and non-refereed articles; 7 lay books and 8 educational booklets for women.

In June 2004 she was awarded Honorary Membership by the Society of Obstetricians and Gynaecologists of Canada (SOGC).
David Greenberg, MD

Dr. Greenberg is a Lecturer at The University of Toronto, and is a member of the Department of Family and Community Medicine at St. Joseph’s Health Centre in Toronto. He has helped to develop and implement a number of educational initiatives for the public and primary care Physicians and Specialists. He was appointed as a director of The Canadian Society for the Study of the Aging Male (CSSAM) in 2003, becoming President in 2008 and continues to hold this position. He is the Chairman of the Review Panel for the Men’s Health Guidelines for Family Medicine, which are available to all Family Doctors in Canada, and have been adapted for use in the UK. Dr. Greenberg was a founding Director of The Canadian Men’s Health Foundation, an NGO founded by Dr. Larry Goldenberg to promote the health of men of all ages across Canada.

Wayne J. G. Hellstrom, MD, FACS

Dr. Hellstrom, a Fellow of the American College of Surgeons, is a Professor of Urology and Chief of Andrology at Tulane University School of Medicine in New Orleans, Louisiana. He is also a urologist at Tulane University and Charity Hospitals and the Veterans Administration Medical Center in New Orleans. Dr. Hellstrom received his MD from McGill Medical School in Montreal, followed by a residency in General Surgery at Montreal General and Royal Victoria Hospital–McGill University in Montreal. He completed a residency in Urology at the University of California, San Francisco, and an AUA scholar-funded fellowship in Andrology at the University of California at Davis from 1986 to 1988. He is board certified in Urology.

He was granted the Young Andrologist Award by the ASA in 1994. Dr. Hellstrom’s research interests include male infertility, erectile dysfunction, prosthetic surgery, genitourinary reconstruction, sperm stimulation protocols for improving motion parameters of sperm, development of new vasoactive erection drugs in animal models, Peyronie’s disease (both basic research and clinical studies), development of new drugs treating premature ejaculation and male hormone deficiency. He also researches gene therapy topics for the treatment of erectile dysfunction, Peyronie’s Disease, and urethral stricture disease.

Dr. Hellstrom has authored or coauthored over 100 book chapters, and nearly 500 manuscripts in peer-reviewed journals. He is the editor of several textbooks in the field of Andrology, including “Male Infertility and Sexual Dysfunction,” “The Handbook of Sexual Dysfunction,” and “Androgen Deficiency and Testosterone Replacement.” He is an Associate Editor for Urology (Gold), and serves on the editorial board on a number of journals, including the Journal of Urology. Dr Hellstrom is also a reviewer for the Journal of Clinical Investigation, Urology, The Journal of Urology, New England Journal of Medicine, and Journal of Andrology.

Tung-Chin Hsieh, MD

Dr. Hsieh is currently the Director of Male Fertility and Men’s Health and an Associate Professor of Urology in the Urology Department of the University of California, San Diego Health System. Dr. Hsieh is an active member of the American Urologic Association, the American Society of Reproductive Medicine, the Society of Male Reproduction and Urology, the Society for the Study of Male Reproduction and the Sexual Medicine Society of North America. Dr. Hsieh received his Bachelor of Science in Biology and Chemistry at Emory University in Atlanta, Georgia. Then he went on to receive his Doctor of Medicine from the University of Vermont College of Medicine in Burlington, Vermont. He then completed his General Surgery Internship/Residency and Urology Residency at George Washington University Hospital. Dr. Hsieh completed his Male Reproductive Medicine and Microsurgery Fellowship at Baylor College of Medicine.

T. Hugh Jones, MD

Dr. Jones is Consultant Physician and Endocrinologist at Barnsley NHS Foundation Trust and Honorary Professor of Andrology at the University of Sheffield Medical School. He is also Honorary Consultant Endocrinologist at the Royal Hallamshire Hospital, Sheffield. He trained in Biochemistry and subsequently medicine at Sheffield University. Postgraduate training in Medicine, Diabetes and Endocrinology in Sheffield and was Lecturer in Medicine at Sheffield University.

Dr. Jones is on the European Association (EAU) of Urology Guideline committee for Male Hypogonadism and the British Society of Sexual Medicine (BSSM) Guideline committee for Adult Testosterone Deficiency. He is Chair of the Academic sub-committee of the Association of British Clinical Diabetologists (ABCD). He is a founding member of the Andrology Society, an international society which is a forum for experts from different medical and scientific disciplines to present and discuss new research into the role of androgens.

The main research theme of the group is the laboratory and clinical investigation of the role of testosterone in the pathogenesis and treatment of coronary heart disease, angina, heart failure, type 2 diabetes and the metabolic syndrome in men. Major discoveries have demonstrated that there is a high prevalence of symptomatic testosterone deficiency in men with T2D and that low testosterone is associated with an increased risk of mortality within populations of men with coronary heart disease and also in type 2 diabetes. Testosterone replacement improves cardiac ischaemia in angina, functional exercise capacity in heart failure, insulin resistance and mortality in type 2 diabetes. Laboratory work has investigated the action of testosterone as an arterial vasodilator, atheroprotective in early arterial lipid streak formation, and its role in glucose and lipid metabolism and an effect on fat depot distribution.
Daniel Kelly, PhD

Dr. Kelly is a lecturer in Biochemistry at Sheffield Hallam University with research interests in cardiovascular disease, type 2 diabetes, obesity and the role of testosterone in these diseases. Following his PhD studying the anti-inflammatory effects of testosterone on atherosclerosis, Dr. Kelly undertook a postdoc at the University of Sheffield to work with Professor Hugh Jones to investigate the tissue-specific actions of testosterone related to the pathogenesis of type 2 diabetes and cardiovascular disease. This research continues at Sheffield Hallam University and extends through ongoing collaborations with partners at the University of Sheffield, University of Chile, Barnsley NHS foundation trust and Bayer HealthCare where he is currently using cell culture systems, pre-clinical models and medical trials of replacement therapy to uncover the underlying mechanisms of testosterone action. Dr. Kelly has an honorary lectureship position at the University of Sheffield allowing close collaboration across the Sheffield Universities. He is the deputy course leader for the undergraduate Biomedical Science degree at Sheffield Hallam University where he uses his current and prior research to inform his teaching in areas related to metabolism, endocrinology, cell biology and biological basis of disease.

Mohit Khera, MD, MBA, MPH

Dr. Khera earned his undergraduate degree at Vanderbilt University. He subsequently earned his Masters Degree in Business Administration and his Masters Degree in Public Health from Boston University. He received his Medical Degree from The University of Texas Medical School at San Antonio and completed his Residency training in the Scott Department of Urology at Baylor College of Medicine. After finishing a six-year residency in Urology, he completed a one-year fellowship in Male Reproductive Medicine and Surgery with Dr. Larry I. Lipshultz.

Dr. Khera is currently a Professor in the Scott Department of Urology at Baylor College of Medicine, where he specializes in Male Infertility and Male and Female Sexual Dysfunction and testostosterone therapy. He also serves as the Director of the Laboratory for Andrology Research at Baylor College of Medicine and Medical Director of the Houston Hospital for Specialized Surgery. He was recently appointed as the Medical Director for Baylor College of Medicine’s Executive Health Program.

Dr. Khera is an enthusiastic investigator in the laboratory. In 2006 he was awarded the American Urological Association and Pfizer Scholars Grant to study erectile dysfunction; in 2007 he was awarded an Auxilium Pharmaceutical Grant to study testosterone replacement therapy for prostate cancer patients, and in 2008 he was awarded an Allergan grant to study the effects of botulinum toxin in treating Peyronie’s disease. These studies continue, and in 2012 Dr. Khera was awarded one of two national grants to study sexual dysfunction in men taking finasteride. Also in 2012 he patented a new delivery system for testosterone and currently his laboratory is studying stem cells to treat sexual dysfunction.

He is a widely published writer, having co-authored book chapters including those for the acclaimed Campbell-Walsh Urology textbook, for Clinical Gynecology, and for the fourth edition of Infertility in the Male edited by Lipshultz, Howards, and Niederberger. He also co-edited the third and most recent edition of the popular book Urology and the Primary Care Practitioner. In 2014 he published his second book “Recoupling: A Couple’s 4 Step Guide to Greater Intimacy and Better Sex”. Dr. Khera has published over 100 articles in scientific journals and has given over 200 lectures throughout the world on testosterone replacement therapy and sexual dysfunction.

Noel N. Kim, PhD

Dr. Kim is a Senior Investigator at the Institute for Sexual Medicine in San Diego, as well as an associate editor of Sexual Medicine Reviews. A member of the AUA, ISSM, ISSWSH, and SMSNA, Dr. Kim has been engaged in research on the physiology of sexual dysfunction since the mid-1980s. He has published and lectured extensively, and has participated in the training of numerous students and fellows in sexual medicine. He was among the early investigators to describe the role of nitric oxide in penile erection and has consistently contributed to the field of sexual medicine, being recognized with numerous research prizes from various sexual medicine societies. He previously served as the Assistant Director of the Laboratory for Sexual Medicine Research at the Boston University School of Medicine and was a member of the editorial board of The Journal of Sexual Medicine for the first decade of the journal through 2014. From 2007 through 2012, Dr. Kim served as Chief Scientific Officer of Alagin Research, a biotechnology company devoted to developing therapeutics and diagnostics in sexual medicine. Dr. Kim continues to serve as a consultant to other companies developing therapies for sexual dysfunction. Dr. Kim received his BA in biology, MA in biochemistry and PhD in physiology from Boston University and completed a research fellowship in cardiology at the University of California, San Diego.

Daniel H. Levi

As counsel in the Litigation Department, Daniel H. Levi has handled complex litigation in a variety of substantive areas including products liability, M&A litigation, antitrust, actuarial malpractice and general commercial disputes. He has handled all aspects of pre-trial, trial and appellate work in state and federal courts, as well as civil and criminal regulatory matters and internal investigations with a particular focus on anti-money laundering.

Matters in which Mr. Levi has had extensive involvement include:

- Representation of Fresenius SE & Co., a German healthcare company, in successful litigation against Akorn, Inc., a U.S.-based pharmaceutical manufacturer, where the Delaware Court of Chancery ruled that Fresenius was justified in canceling its $4.8 billion merger agreement on grounds of a material adverse change in Akorn’s business. Representation of AbbVie, Inc. in MDL litigation and multiple bellwether trials concerning the safety of the testosterone replacement therapy drug AndroGel. Representation of The Alaska Retirement Management Board, trustee of Alaska’s public pension and welfare plans, in a suit against the State’s former actuary, Mercer (US) Inc., claiming that Mercer’s malpractice contributed to at least $1.8 billion to Alaska’s pension shortfall. Matter was settled favorably for $500 million. Representation of Citigroup in defense of a $2 billion claim brought by the Italian dairy company Parmalat. Citigroup defeated the claim and obtained judgment at trial on its counterclaim for $364 million, which was affirmed by the New Jersey Appellate Division. Representation of FIFA in litigation concerning concussions in youth soccer in which FIFA won a motion to dismiss the claims. Mr. Levi served as notes editor of the Washington University Law Quarterly. He was selected as one of the school’s three Honors Scholars and was elected to the Order of the Coif.
Peter H. Lim, MD

Dr. Lim is Senior Consultant Urologist and Medical Director of Andrology, Urology & Continence Centre at Gleneagles Hospital, Singapore. He also serves as Adjunct Professor (Men’s Health) at Cowen University, Western Australia and Honorary Professor in Urology and Andrology at the HT Naval Medical School in Indonesia. Founder President of the Society for Men’s Health (Singapore), Dr. Lim was also founder President of the Society for Continence, Singapore, President of the Asia-Pacific Continence Advisory Board and the Asian Society for Female Urology. A member of many international societies, including the American Urological Society, the International Society for Sexual Medicine, Dr. Lim serves on the editorial board of various journals. He has also published many peer-review journals and has also contributed to nine books, latest on Men’s Health published by Springer-Verlag in 2013. Dr. Lim was conferred the Honorary Membership of the Institute of Urology, London (1992), the Singapore Urological Association Lectureship of the Year 2001 and the Eminent reviewer Award of the SMJ & the Eminent Scientist of the Year award 2003 from the World Scientists Forum. Dr. Lim’s research interests and specialties include andrology, erectile dysfunction, incontinence and general urology.

Larry I. Lipshultz, MD

Dr. Lipshultz is Professor of Urology and Chief of the Scott Department of Urology’s Division of Male Reproductive Medicine and Surgery at Baylor College of Medicine in Houston, Texas. Dr. Lipshultz, who holds the Lester and Sue Smith Chair in Reproductive Medicine, is a well-known authority on abnormalities of male reproduction, erectile dysfunction and male hormone therapy. He completed his medical training and urology residency at the University of Pennsylvania and was the first American Urological Association (AUA) research scholar. He is a member of the American Association of Genitourinary Surgeons, a founder of the Society for the Study of Male Reproduction and the American Society of Andrology, and is the second urologist elected President of the American Society for Reproductive Medicine (ASRM).

Dr. Lipshultz has been an active member of the AUA throughout his career. Among many other activities, he has served on the FDA Advisory Committee for Reproductive Health Drugs. In 2010 he was honored by the AUA as “one of the most respected surgeon scientists and mentors in Urology.” He received the ASRM Service Award in 2011, the AUA’s Hugh Hampton Young Award in 2005, and the F. Brantley Scott Award of Excellence in 2015. He has published more than 400 journal articles, serves on the editorial boards of several major journals, and has edited two widely used comprehensive text books. He is frequently invited to lecture in the US and abroad, and he is listed routinely in Best Doctors in America and Castle Connolly’s America’s Top Doctors. Teacher as well as physician, researcher, writer, and editor, Dr. Lipshultz instituted a fellowship training program in male reproductive medicine and surgery that has trained more than 100 physicians who are now in practice both here and abroad.

Andrew R. McCullough, MD

Dr. McCullough joined the full time faculty at the Albany Medical Center as Professor of Surgery/Urology and director of Andrology in 2011. Previously, he was Associate Professor in the Department of Urology at the New York University (NYU) School of Medicine in New York. He earned his medical degree from the University of Maryland School of Medicine in Baltimore, completed his internship in surgery at the University of Florida in Gainesville, and a urology residency and William Wallace Scott Uro-Oncology fellowship at the Johns Hopkins School of Medicine in Baltimore, Maryland.

He has served on the faculty in urology at The Johns Hopkins School of Medicine, Yale University School of Medicine, New York University School of Medicine and is currently at Albany Medical College. He served as Vice Chairman of the NYU Institutional Review Board and currently serves on the Albany Medical College IRB.

He is an internationally recognized expert and educator in sexual health and fertility and has presented his research work in at major conferences throughout the world. Dr. McCullough continues to investigate new medical and surgical therapies for the treatment of male sexual dysfunction, hypogonadism and infertility. He has published extensively on sexual rehabilitation after radical prostatectomy and has served as principal investigator in over 50 major clinical trials in male and female sexual dysfunction, post prostatectomy penile rehabilitation, male infertility and BPH. While at NYU, he was a weekly host for the Men’s Health Show on the Sirius 114 and XM 119 Doctor Radio Channel.

Currently he is the director of an Andrology and Male Prosthetic and Reconstructive Surgery fellowship at the Albany Medical College. He serves as reviewer for the Journal of Urology, Urology, International Journal of Impotence Research, Asian Journal of Andrology and Andrology.

Martin M. Miner, MD

Dr. Miner is Director of the Men’s Health Center of Miriam Hospital, in Providence, Rhode Island. He is a Clinical Associate Professor of Family Medicine and Urology at Warren Alpert Medical School of Brown University, in Providence, and Co-Director of the Men’s Health Center there. Dr. Miner graduated Phi Beta Kappa from Oberlin College and received a Doctor of Medicine degree from the University of Cincinnati College of Medicine, both in Ohio. He completed a residency at Brown University and worked with the Indian Health Service Corps and the Public Health Service. Active on several journal editorial boards, Dr. Miner also serves as a reviewer and has published extensively in the areas of erectile dysfunction, cardiovascular disease, benign prostatic hyperplasia, lower urinary tract symptoms, male sexuality and hormone therapy for men. He has given numerous presentations in the United States and internationally, is active in several research studies on men’s health and is a consultant to the International Society of Sexual Medicine Consensus Panel.

Dr. Miner holds memberships in the American Academy of Family Physicians and the American Urologic Association and was elected a Fellow of the Sexual Medical Society of North America where he was on the BOD until this year. He was chosen the Brown Teacher of the Year in 2003 and 2007 and was recognized with the Massachusetts Medical Societys Award on greatest contribution to Mens Health: 2012.
Abraham Morgentaler, MD, FACS

Dr. Morgentaler, the Director of Men’s Health Boston, is an Associate Clinical Professor of Urology at Beth Israel Deaconess Medical Center and Harvard Medical School. Dr. Morgentaler lectures nationally and internationally to teach physicians the latest information in the diagnosis and treatment of conditions affecting men’s sexual and reproductive health. His primary areas of interest are testosterone deficiency, male sexual dysfunction, and prostate cancer. He is the President of the Androgen Society, an international multidisciplinary professional organization the promotes research and education regarding testosterone deficiency and its treatment.

Dr. Morgentaler has published over 175 scientific articles and textbook chapters. He is a regular contributor to television and radio shows addressing male issues, and has appeared on NBC Nightly News, CBS Evening News, CNN with Anderson Cooper, and The Connection on NPR. Dr. Morgentaler and his clinical work with testosterone were featured in The New Yorker, and his comments have been published in journals such as Newsweek and US News and World Report.

He is the author of several popular books, including, _The Truth About Men And Sex: Intimate Secrets From the Doctor’s Office, The Viagra Myth: The Surprising Impact on Love and Relationships, _and _Testosterone for Life: Recharge Your Vitality, Sex Drive, Muscle Mass, and Overall Health._

Amy Nemetz

Amy Nemetz is a Litigation Associate at Paul, Weiss, Rifkind, Wharton & Garrison LLP in New York City. She focuses on complex products liability, securities fraud, and commercial disputes, and has a wide-ranging pro bono practice involving immigration and civil rights issues. Ms. Nemetz completed a clerkship for the Honorable Jan E. DuBois of the US District Court for the Eastern District of Pennsylvania. She received her JD, magna cum laude, from New York University School of Law in 2014, and her BA, magna cum laude, in History from New York University in 2011.

Sharon J. Parish, MD

Dr. Parish is a Professor of Medicine in Clinical Psychiatry and Professor of Clinical Medicine at the Weill Cornell Medical College and the Director of Medical Services at the New York Presbyterian Hospital/Westchester Division. Dr. Parish is an internal medicine physician who is a fellow of the International Society for the Study of Women’s Sexual Health (ISSWSH) and a North American Menopause Society Certified Menopause Practitioner. She has an internal medicine practice focusing on sexual medicine for female and male patients at Weill Cornell Medicine in New York City.

Dr. Parish has a special interest in practice, training, and research in sexual medicine and menopause. She has designed many educational programs on sexual health and sex medicine communication skills for undergraduate, graduate and postgraduate medical education and across multiple disciplines. She has authored many publications and online materials on an array of topics including female and male sexual dysfunction classification, clinical assessment and therapeutic interventions; sexuality communication skills and education; erectile dysfunction, premature ejaculation, hormonal therapy and genitourinary syndrome of menopause/vulvovaginal atrophy. Her academic activities have also included participation in international and national society committees and consultancies; lectures, symposia, and web-based educational programs; and sexual medicine society leadership roles.

She is Past President of the ISSWSH (2014-2018), Chair of the ISSWSH Clinical Practice Guidelines Committee (2016-2018), a member of the ISSWSH Board of Directors (2001-present), the ISSWSH Scientific Program Chair (Annual Meetings 2018, 2019), and was Chair of the ISSWSH Education Committee from 2002-2014. She is a member of the International Society for Sexual Medicine (ISSM) Board of Directors (2018-2022) and Education and Corporate Relations Committees. Dr. Parish is an Associate Editor for Sexual Medicine Reviews (2017-present) and previously Associate Editor for CME (2006-2014) and Assistant Editor for Female Medical/Surgical for the Journal of Sexual Medicine (2014-2016).

Sudarshan Ramachandran, PhD, FRCPath

Originally from Sri Lanka, Professor Ramachandran trained as an undergraduate in London (Imperial College, University of London) and was accepted onto the specialist training programme in Chemical Pathology in the West Midlands. He was appointed a Consultant Chemical Pathologist at the University Hospitals Birmingham and Senior Lecturer at the University of Birmingham in 2000. He completed a PhD in 2004 conducting research into the role of genetics in cancer, using basal cell carcinoma as a cancer model. The work then went on to include other conditions associated with UV exposure such as prostate cancer and multiple sclerosis.

In 2015 he was appointed to the newly created chair of Metabolic Medicine at the University Hospitals of North Midlands. His work on blood flow characteristics enabled him to be appointed as Professor (Hon) of Biomedical Engineering at Brunel University London. Professor Ramachandran’s research and clinical work is now focused on the Metabolic Syndrome, its components and associated conditions including obesity, diabetes/pre-diabetes, dyslipidaemia, hypertension, non-alcoholic fatty liver disease, testosterone deficiency and cardiovascular disease prevention.

Ranjith Ramasamy, MD

Dr. Ramasamy is the Director of Male Reproductive Medicine and Surgery as well as an Assistant professor in Department of Urology at the University of Miami. As a Urologist and Microsurgeon, Dr. Ramasamy specializes in the treatment of disorders of male infertility and sexual dysfunction and an expert in vasectomy reversal and penile prosthesis. Dr. Ramasamy completed his Urology residency training at Weill Cornell Medical College and New York-Presbyterian Hospital. He then completed a National Institutes of Health sponsored fellowship in Male Reproductive Medicine and Surgery at Baylor College of Medicine. In addition to his clinical accolades, Dr. Ramasamy has been integral to the advancement of male reproductive medicine and surgery. To date, he has published over 100 manuscripts in peer-reviewed journals and several book chapters; he currently serves on editorial board for _Urology, and Asian Journal of Andrology_ and as an editorial reviewer for _Journal of Urology, European Urology and British Journal of Urology_. Furthermore, he has been invited to lecture at numerous international conferences including the American Urological Association, Malaysian and Indian Society of Assisted Reproduction.
Farid Saad, DVM, PhD

Dr. Saad was born in Alexandria, Egypt. He studied human and veterinary medicine and became a specialist for reproductive endocrinology, pediatric endocrinology, and andrology from Ferring GmbH in Kiel, Germany. From 1998 – 2001 Dr. Saad was the leader of clinical development andrology at Jenapharm in Jena, Germany as well as a specialist in endocrinology of aging, male aging, male hormonal fertility control. From 2001 – 2007 he was the leader of the product group, "Male Health Care" at Schering AG in Berlin, Germany. Dr. Saad has authored and co-authored more than 120 peer-reviewed papers and more than 60 scientific abstracts. In 2005, Dr. Saad obtained honorary professorship in clinical research and endocrinology at Gulf Medical University in Ajman, United Arab Emirates. In 2006, he obtained honorary professorship at Men’s Health Reproduction Study Center, Hang Tuah University in Surabaya, Indonesia. In 2016, Dr. Saad became lecturer at Dresden International University in Dresden, Germany.

Abdul Traish, MBA, PhD

Dr. Traish earned a B.Sc., in Chemistry & Botany from the University of Tripoli, Tripoli, Libya in 1971 and a PhD, in Biochemistry from Boston University, Boston, Massachusetts in 1978. After two years of training as a postdoctoral Fellowship in the Department of Biochemistry at Boston University School of Medicine, he was appointed as an assistant research professor of Biochemistry. Dr. Traish also earned Master of Business Administration (MBA) from Boston University School of Management in 1993. Since 1979, Dr. Traish was collaborating with faculty in the Urology Department and in 1996 he was promoted to full professor in the Department of Biochemistry and Department of Urology.

Dr. Traish pursued basic research, in the field of steroid biochemistry and physiology of reproductive and sexual medicine. His contributions to the field of sexual medicine include the development of experimental animal models to investigate the endocrine regulation of sexual arousal physiology and function in males and females and his pioneering work on the basic mechanisms of sex steroid hormones on erectile physiology. Dr. Traish has been successful in procuring research funds from the National Institute of Health as well as from the Private Sector and was instrumental in the establishment of the institute for sexual medicine at Boston University school of Medicine. Dr. Traish is a researcher with renowned national and international reputation.

Dr. Traish taught Biochemistry to graduate and medical students for more than 28 years. He had served as an advisor/mentor for more than 100 graduate and medical students. He also mentored doctoral students (PhD) who completed their research dissertation in his laboratory. Dr. Traish has advised and served as mentor for physician-scientists, medical residents and research fellows from several countries including Italy, South Korea, Turkey, Greece and the USA, who sought research training in his laboratory.

Randall J. Urban, MD

Dr. Urban is currently the Vice President and Chief Research Officer as well as Vice Dean, Clinical Research SOM Professor in the Department of Internal Medicine of the University of Texas Medical Branch in Galveston, Texas. Dr. Urban received his BS in Biochemistry as well as his MD from Texas A&M University in College Station, Texas. He went on to complete his Internal Medicine Residency at Mayo Clinic in Rochester, Minnesota and his Endocrinology Fellowship at the University of Virginia Medical School in Charlottesville, Virginia.

Tamara L. Wexler, MD, PhD

Dr. Wexler is an endocrinologist specializing in neuroendocrinology and reproductive endocrinology. She has served as an Attending Physician in Internal Medicine at the Massachusetts General Hospital and as the Director of the NYU Langone Medical Center Pituitary Center, where she built the infrastructure to facilitate clinical research, and focused on enhancing the study and care of neuroendocrine and reproductive endocrine issues through research and direct clinical care.

Dr. Wexler’s research interests center on neuroendocrine and reproductive endocrine changes, including those that may occur after traumatic brain injury (TBI). She established the NYU Endocrine Registry to support clinical research, and initiated multidisciplinary and inter-institute research collaborations to further investigate the importance of pituitary dysfunction and its treatment. She serves as the principal investigator of NYU’s cross-departmental TBI/Pituitary research and the lead site investigator for a multisite neuroendocrine tumor study.

Dr. Wexler received her medical degree and PhD in Neuroscience from the University of Pennsylvania, conducting dissertation research into the pathophysiology of Kallmann’s Syndrome at the University of Pennsylvania and the National Institutes of Health. She completed her residency in Internal Medicine and fellowship in Endocrinology, Diabetes, and Metabolism at the Massachusetts General Hospital, where she was part of the multidisciplinary Neuroendocrine Unit, designed and ran national clinical trials on the impact of growth hormone, and served for 12 years on the MGH Optimum Care Committee and on the Ethics Task Force.

While remaining on staff at the Massachusetts General Hospital, Dr. Wexler spent four years at McKinsey & Company, where she served as the Global Lead for Endocrinology. She reviews grants for the Bill and Melinda Gates Foundation in the area of reproductive health; is an invited member of the University of Pennsylvania Institute for Diabetes, Obesity, and Metabolism Leadership Council; consults as an expert on research and development programs; and serves on the editorial board of Endocrine Today. She is an active member of The Endocrine Society, for which she served on the Advocacy and Public Outreach core committee, and was recently elected to the Scientific and Educational Programs Core Committee. She is a speaker and moderator at academic medical centers and national conferences on the topic of pituitary function, reproductive endocrinology, and post-TBI endocrine disorders.

Her publications appear in the Journal of Clinical Endocrinology & Metabolism and Clinical Endocrinology, among other journals.
INDUSTRY SATELLITE SYMPOSIUM EVENT

THURSDAY, MARCH 21, 2019

12:00 p.m. - 1:00 p.m.

Industry Satellite Symposium Lunch
Location: Fulton

“A New TRT Auto-Injector in the Management of Hypogonadism”

Jed C. Kaminetsky, MD
Clinical Assistant Professor, Department of Urology
New York University Langone Health and University Urology Associates

Sponsored By: Antares Pharma

FRIDAY, MARCH 22, 2019

7:00 a.m. - 8:00 a.m.

Industry Satellite Symposium Breakfast
Location: Fulton

“Treating Male Hypogonadism, and Why Pulsatility Matters”

Ross Ormsby, PhD
Acerus Pharma
Ontario, Canada

Ranjith Ramasamy, MD
Director of Male Reproductive Medicine and Surgery
University of Miami
Miami, Florida

Sponsored By: Acerus Pharmaceuticals

12:00 p.m. - 1:00 p.m.

Industry Satellite Symposium Lunch
Location: Fulton

“Testosterone Insufficiency and Treatment in Women: International Expert Consensus Resolutions”

Gary S. Donovitz, MD
BioTe Medical Founder & Chairman
Irving, Texas

Sponsored By: BioTE Medical
THANK YOU TO OUR 2019 PROMOTIONAL PARTNERS

Diamond Level Partner

Antares Pharma

Platinum Level Partners

Acerus Pharma

BioTE Medical

Gold Level Partner

Endo Pharmaceuticals
THANK YOU TO OUR 2019 EXHIBITORS
(Alphabetical as of 3/12/2019)

Acerus Pharmaceuticals
Antares Pharma
Belmar Pharmacy
BioTE Medical, LLC
Empower Pharmacy
Endo Pharmaceuticals
Timm Medical Technologies

THANK YOU TO OUR 2019 CONTRIBUTOR
(Alphabetical as of 3/12/2019)

Clarus Therapeutics, Inc.
<table>
<thead>
<tr>
<th>Company Name</th>
<th>Table #</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acerus Pharmaceuticals</td>
<td>6</td>
</tr>
<tr>
<td>Antares Pharma</td>
<td>7</td>
</tr>
<tr>
<td>Belmar Pharmacy</td>
<td>5</td>
</tr>
<tr>
<td>BioTE Medical, LLC</td>
<td>1</td>
</tr>
<tr>
<td>Empower Pharmacy</td>
<td>3</td>
</tr>
<tr>
<td>Endo Pharmaceuticals</td>
<td>2</td>
</tr>
<tr>
<td>Timm Medical Technologies</td>
<td>4</td>
</tr>
</tbody>
</table>
Androgen Society
Two Woodfield Lake
1100 E. Woodfield Road, Suite 350
Schaumburg, IL 60173